A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DC-806 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Intervention/treatment:
DC-806
Medical condition:
PLAQUE PSORIASIS
Protocol code:
DCE806201
Control number:
274313
Status:
Closed
Approved:
May 17, 2023
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05896527
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 70 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Chief Medical Officer
Organization
Eli Lilly and Company
Phone:
800-545-5979
Sponsor
DICE THERAPEUTICS, INC.

Locations

Alberta

Alberta DermaSurgery Centre - Probity - PPDS
Edmonton, Alberta, T6G 1C2

British Columbia

Enverus Medical Research - Probity - PPDS
Surrey, British Columbia, V3V 0C6

Manitoba

Wiseman Dermatology Research Inc. - Probity - PPDS
Winnipeg, Manitoba, R3M 3Z4

Ontario

Alliance Clinical Trials - Probity - PPDS
Waterloo, Ontario, N2J 1C4
CCA Medical Research - Probity - PPDS
Ajax, Ontario, L1S 7K8
Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
Québec, Ontario, G1V 4X7
Dermatrials Research
Hamilton, Ontario, L8N 1Y2
DermEdge Research Probity - PPDS
Mississauga, Ontario, L4M 7G1
DICE Therapeutics Study Site
North York, Ontario, M2M 4J5
Lynderm Research Inc. - Probity - PPDS
Markham, Ontario, L3P 1X2
SimcoDerm Medical and Surgical Dermatology Centre - Probity - PPDS
Barrie, Ontario, L4M 7G1

Results

See the results from the trial NCT05896527. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?